AMPLATZER™ LAA Occluder Post Approval Study (PAS)
Launched by ABBOTT MEDICAL DEVICES · Nov 10, 2016
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • Documented history of nonvalvular atrial fibrillation
- • Subjects in whom an AMPLATZER LAA Occluder device is intended to be implanted or Subjects who underwent an AMPLATZER LAA Occluder implant attempt after the device was approved in the applicable geography
- Exclusion Criteria:
- • Women of childbearing potential who are, or plan to become, pregnant during the time of the study
About Abbott Medical Devices
Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Vancouver, British Columbia, Canada
Ottawa, Ontario, Canada
Barcelona, , Spain
Majadahonda, Madrid, Spain
Napoli, Campania, Italy
Montreal, Quebec, Canada
Bad Segeberg, Schleswig Holstein, Germany
Lodelinsart, Hainaut, Belgium
Padova, Veneto, Italy
Salamanca, Castile And Leon, Spain
Frankfurt, Hesse, Germany
Rosario, Santa Fe, Argentina
New Westminster, British Columbia, Canada
Vancouver, British Columbia, Canada
Montreal, Quebec, Canada
Montréal, Quebec, Canada
Providencia, Santiago, Chile
Santiago, , Chile
Bonn, North Rhine Westphalia, Germany
Bad Berka, Thuringia, Germany
Torino, Piedmonte, Italy
Patients applied
Trial Officials
Ryan Palmer
Study Director
Abbott
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials